Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
Sign Up to like & getrecommendations! Published in 2019 at "Advances in chronic kidney disease"
DOI: 10.1053/j.ackd.2019.04.007
Abstract: Anemia is a well-known complication of advanced CKD and treatment with erythropoietin analogues (epoetin) remains a key component of management. Although biologic agents, including epoetin, play an extremely important role in the treatment of various… read more here.
Keywords: disease biosimilar; biosimilar erythropoiesis; kidney disease; chronic kidney ... See more keywords
Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13910
Abstract: Erythropoiesis‐stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B‐ESA), in myelofibrosis (MF) is not well established. read more here.
Keywords: biosimilar erythropoiesis; erythropoiesis stimulating; agents effective; myelofibrosis ... See more keywords